At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
Allergy & Immunology
